PharmaAust Appoints New CEO for Epichem

  • Oct 14, 2019 AEDT
  • Team Kalkine

Clinical-stage oncology company, PharmaAust Ltd (ASX: PAA) has announced the appointment of Mr. Colin La Galia as new Chief Executive for its wholly-owned subsidiary – Epichem.

Who is Mr. Colin?

  • Colin is a highly experienced executive in phamaceuticals, devices and diagnostics, who was previously the Regional Business Director and Commercial Head of Asia Pacific, China and Japan for Abbott Rapid Diagnostics;
  • Colin has held senior roles for over 20 years at various big firms like Alere Inc, Origin Healthcare, Hollywood Fertility Centre, GlaxoSmithKline and Merck Sharpe & Dohme.

By 01:04 PM AEST, PAA was trading at $0.13, up by 4% relative to the last close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK